Feature | Heart Valve Technology | July 28, 2015

Boston Scientific Announces CE Mark and FDA Clearance for Safari2 Pre-Shaped Guidewire

Guidewire designed specifically for TAVI/R now sized for smaller ventricles

July 28, 2015 — Boston Scientific announced CE Mark and U.S. Food and Drug Administration (FDA) clearance for the Safari2 Pre-Shaped Guidewire. Safari2 is an enhanced version of the  Safari Guidewire, intended to facilitate the introduction and placement of interventional devices within the heart, including those used with transcatheter aortic valve implantation or replacement procedures (TAVI/R). The Safari2 Guidewire is compatible for use with all TAVI/R devices.

The device provides a streamlined delivery with enhanced wire predictability and shape retention for interventional devices within the heart. Additionally, the Safari2 product line offers the widest guidewire choice with three curve sizes, including a new extra small curve designed for procedures involving patients with smaller ventricles, a current unmet need in this population.

Having a pre-shaped, universal TAVR guidewire helps physicians deliver the replacement valve with reliability and consistency,” said Wesley Pederson, M.D., director of valve and structural heart disease at the Minneapolis Heart Institute. “This is a wonderful development to have a smaller curve size so that we can offer this less invasive treatment option to a broader range of patients because valvular disease can have a devastating impact on patient survival and quality of life.”

The Safari2 Guidewire complements the Boston Scientific Lotus Valve System, designed to give physicians more control throughout the TAVI/R procedure.

For more information: www.bostonscientific.com

Related Content

Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve has been approved with CE mark for use in Europe.
Feature | Heart Valve Technology | February 15, 2018
February 15, 2018 — Edwards Lifesciences Corp.
Boston Scientific Enters Investment and Acquisition Option Agreement With Millipede
News | Heart Valve Technology | January 24, 2018
Boston Scientific Corp. announced it has closed an investment and entered into an acquisition option agreement with...
Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System
News | Heart Valve Technology | January 11, 2018
The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery...
Videos | Heart Valve Technology | January 04, 2018
Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how hi
Edwards Acquires Harpoon Medical
News | Heart Valve Technology | December 07, 2017
December 7, 2017 — Edwards Lifesciences Corp.
Videos | Heart Valve Technology | November 15, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, is the principal investigato
New Analyses Reinforce Hemodynamic Benefits of Evolut TAVR Platform in Intermediate-Risk Aortic Stenosis Patients
News | Heart Valve Technology | November 08, 2017
Medtronic plc recently presented new clinical research to support the positive clinical performance of the Evolut...
Videos | Heart Valve Technology | November 08, 2017
Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at Morris
Videos | Heart Valve Technology | November 08, 2017
Stephen Worthley, MB, BS, Ph.D., director of cardiac catheterization, University of Adelaide, Australia, presents the
Overlay Init